资料显示，河北常山生化药业股份有限公司位于中国(河北)自由贸易试验区正定片区正定县高新技术产 业开发区南区梦龙街71号，成立日期2000年9月28日，上市日期2011年8月19日，公司主营业务涉及肝素 系列产品的研发、生产和销售。主营业务收入构成为：水针制剂47.47%，肝素原料药39.24%，其他 13.29%。 1月12日，常山药业跌2.02%，截至发稿，报57.79元/股，成交14.94亿元，换手率2.74%，总市值531.13 亿元。常山药业股价已经连续3天下跌，区间累计跌幅9.33%。 风险提示：市场有风险，投资需谨慎。本文为AI大模型自动发布，任何在本文出现的信息（包括但不 限于个股、评论、预测、图表、指标、理论、任何形式的表述等）均只作为参考，不构成个人投资建 议。 责任编辑：小浪快报 富国创业板中盘200ETF（159571）成立日期2023年12月20日，最新规模3816.75万。今年以来收益 8.24%，同类排名975/5580；近一年收益48.74%，同类排名1415/4203；成立以来收益60.06%。 富国创业板中盘200ETF（159571）基金经理为葛俊阳。 截至发稿，葛俊阳累计 ...

融券方面，常山药业12月29日融券偿还0.00股，融券卖出0.00股，按当日收盘价计算，卖出金额0.00 元；融券余量100.00股，融券余额6180.00元，超过近一年90%分位水平，处于高位。 资料显示，河北常山生化药业股份有限公司位于中国(河北)自由贸易试验区正定片区正定县高新技术产 业开发区南区梦龙街71号，成立日期2000年9月28日，上市日期2011年8月19日，公司主营业务涉及肝素 系列产品的研发、生产和销售。主营业务收入构成为：水针制剂47.47%，肝素原料药39.24%，其他 13.29%。 12月29日，常山药业跌2.39%，成交额7.43亿元。两融数据显示，当日常山药业获融资买入额7922.24万 元，融资偿还8031.13万元，融资净买入-108.89万元。截至12月29日，常山药业融资融券余额合计26.28 亿元。 截至12月19日，常山药业股东户数3.96万，较上期减少4.57%；人均流通股23203股，较上期增加 4.79%。2025年1月-9月，常山药业实现营业收入6.81亿元，同比减少13.11%；归母净利润-4481.74万 元，同比减少714.77%。 融资方面，常山药业 ...

Group 1 - The core point of the news is that Changshan Pharmaceutical experienced a stock price increase of 5.48%, reaching 56.56 CNY per share, with a trading volume of 1.093 billion CNY and a turnover rate of 2.18%, resulting in a total market capitalization of 51.982 billion CNY [1] - Changshan Pharmaceutical, established on September 28, 2000, and listed on August 19, 2011, specializes in the research, production, and sales of heparin series products, with its main business revenue composition being 47.47% from water injection preparations, 39.24% from heparin raw materials, and 13.29% from other sources [1] Group 2 - From the perspective of major fund holdings, data shows that Guotai Fund has a significant position in Changshan Pharmaceutical, with the Guotai ChiNext Medical and Health ETF (159377) increasing its holdings by 19,500 shares in the third quarter, totaling 45,100 shares, which accounts for 4.75% of the fund's net value, ranking as the fifth-largest holding [2] - The Guotai ChiNext Medical and Health ETF (159377) was established on April 2, 2025, with a latest scale of 43.2788 million CNY and a cumulative return of 21.59% since inception [2]

Core Insights - The stock price of Changshan Pharmaceutical has increased by 160.63% year-to-date, with a recent rise of 7.36% over the last five trading days [2] - The company has a market capitalization of 47.883 billion yuan and reported a trading volume of 7.47 billion yuan on October 21 [1] - Changshan Pharmaceutical's main business includes the research, production, and sales of heparin series products, with revenue composition of 47.47% from water injection preparations, 39.24% from heparin raw materials, and 13.29% from other sources [2] Financial Performance - For the first half of 2025, Changshan Pharmaceutical achieved operating revenue of 492 million yuan, a year-on-year decrease of 13.42%, while the net profit attributable to the parent company was -29.09 million yuan, an increase of 37.98% year-on-year [2] - The company has distributed a total of 181 million yuan in dividends since its A-share listing, with 4.5953 million yuan distributed over the last three years [3] Shareholder Information - As of October 10, 2023, the number of shareholders for Changshan Pharmaceutical was 45,700, a decrease of 2.04% from the previous period, with an average of 20,094 circulating shares per person, an increase of 2.08% [2] - Hong Kong Central Clearing Limited is the fourth largest circulating shareholder, holding 10.5521 million shares, an increase of 8.0391 million shares from the previous period [3]

Group 1 - The core viewpoint of the news highlights the recent performance and financial metrics of Changshan Pharmaceutical, including stock price movements and trading volumes [1][2] - On October 20, Changshan Pharmaceutical's stock rose by 4.60%, with a trading volume of 1.415 billion yuan, and a net financing purchase of 37.36 million yuan [1] - As of October 20, the total margin balance for Changshan Pharmaceutical reached 2.088 billion yuan, accounting for 4.46% of its market capitalization, indicating a high level of financing activity [1] Group 2 - As of October 10, the number of shareholders for Changshan Pharmaceutical was 45,700, a decrease of 2.04%, while the average circulating shares per person increased by 2.08% to 20,094 shares [2] - For the first half of 2025, Changshan Pharmaceutical reported a revenue of 492 million yuan, a year-on-year decrease of 13.42%, and a net profit attributable to shareholders of -29.09 million yuan, reflecting a year-on-year increase of 37.98% in losses [2] - The company has distributed a total of 181 million yuan in dividends since its A-share listing, with 4.5953 million yuan distributed over the past three years [3]

Group 1 - The core point of the news is that Changshan Pharmaceutical experienced a stock price increase of 5.13%, reaching 51.24 CNY per share, with a trading volume of 543 million CNY and a turnover rate of 1.20%, resulting in a total market capitalization of 47.093 billion CNY [1] - Changshan Pharmaceutical, established on September 28, 2000, and listed on August 19, 2011, is primarily engaged in the research, production, and sales of heparin series products, with main business revenue composition being 47.47% from water injection preparations, 39.24% from heparin raw materials, and 13.29% from other products [1] Group 2 - From the perspective of fund holdings, one fund under E Fund has a significant position in Changshan Pharmaceutical, with the E Fund Growth ETF (159572) holding 352,200 shares, accounting for 2.07% of the fund's net value, making it the largest holding [2] - The E Fund Growth ETF (159572) was established on December 15, 2023, with a latest scale of 792 million CNY, and has achieved a year-to-date return of 20.12%, ranking 2291 out of 4218 in its category, and a one-year return of 25.61%, ranking 2080 out of 3865 [2]

Core Viewpoint - Changshan Pharmaceutical's stock has shown significant growth this year, with a year-to-date increase of 147.52%, despite a slight decline in the last five trading days [1] Group 1: Stock Performance - As of October 17, Changshan Pharmaceutical's stock price reached 49.48 CNY per share, with a market capitalization of 454.75 billion CNY [1] - The stock has experienced a trading volume of 1.79 billion CNY, with a turnover rate of 0.40% [1] - The stock has been on the "龙虎榜" (a list of stocks with significant trading activity) five times this year, with the most recent appearance on June 19, where it recorded a net buy of -178 million CNY [1] Group 2: Financial Performance - For the first half of 2025, Changshan Pharmaceutical reported a revenue of 492 million CNY, a year-on-year decrease of 13.42%, while the net profit attributable to shareholders was -29.09 million CNY, an increase of 37.98% year-on-year [2] - The company has distributed a total of 181 million CNY in dividends since its A-share listing, with 4.60 million CNY distributed over the last three years [3] Group 3: Shareholder Information - As of October 10, the number of shareholders for Changshan Pharmaceutical was 45,700, a decrease of 2.04% from the previous period, with an average of 20,094 circulating shares per shareholder, an increase of 2.08% [2] - As of June 30, 2025, Hong Kong Central Clearing Limited was the fourth-largest circulating shareholder, holding 10.55 million shares, an increase of 8.04 million shares from the previous period [3] Group 4: Business Overview - Changshan Pharmaceutical, established on September 28, 2000, and listed on August 19, 2011, specializes in the research, production, and sales of heparin series products [1] - The company's main business revenue composition includes 47.47% from water injection preparations, 39.24% from heparin raw materials, and 13.29% from other sources [1][2]

Core Viewpoint - Changshan Pharmaceutical experienced a 3.44% increase in stock price on October 15, with a trading volume of 1.451 billion yuan, indicating strong market interest and activity [1]. Financing Summary - On October 15, Changshan Pharmaceutical had a financing buy-in amount of 208 million yuan, with a net financing buy of 94.32 million yuan after 114 million yuan in financing repayments [1]. - The total financing and securities lending balance reached 2.093 billion yuan, accounting for 4.54% of the circulating market value, which is above the 90th percentile of the past year, indicating a high level of financing activity [1]. - The securities lending data showed no shares were sold or repaid on October 15, with a remaining balance of 5020 yuan, which is above the 70th percentile of the past year, suggesting a relatively high level of securities lending [1]. Company Performance - As of October 10, the number of shareholders for Changshan Pharmaceutical was 45,700, a decrease of 2.04% from the previous period, while the average circulating shares per person increased by 2.08% to 20,094 shares [2]. - For the first half of 2025, the company reported a revenue of 492 million yuan, a year-on-year decrease of 13.42%, and a net profit attributable to shareholders of -29.09 million yuan, reflecting a 37.98% increase compared to the previous year [2]. Dividend and Shareholding Information - Since its A-share listing, Changshan Pharmaceutical has distributed a total of 181 million yuan in dividends, with 4.5953 million yuan distributed over the last three years [3]. - As of June 30, 2025, Hong Kong Central Clearing Limited was the fourth largest circulating shareholder, holding 10.5521 million shares, an increase of 8.0391 million shares from the previous period [3].

Group 1 - The core point of the news is that Changshan Pharmaceutical experienced a 5.07% increase in stock price, reaching 50.99 CNY per share, with a trading volume of 976 million CNY and a turnover rate of 2.16%, resulting in a total market capitalization of 46.863 billion CNY [1] - Changshan Pharmaceutical, established on September 28, 2000, and listed on August 19, 2011, is primarily engaged in the research, production, and sales of heparin series products [1] - The company's main business revenue composition includes 47.47% from water injection preparations, 39.24% from heparin raw materials, and 13.29% from other products [1] Group 2 - From the perspective of fund holdings, one fund under Yinhua Fund has a significant position in Changshan Pharmaceutical, with the Yinhua ChiNext 200 ETF (159575) holding 4,000 shares, accounting for 2.02% of the fund's net value, making it the largest holding [2] - The Yinhua ChiNext 200 ETF was established on December 20, 2023, with a latest scale of 9.2491 million CNY, and has achieved a year-to-date return of 21.78% [2] - The fund managers, Zhang Yichi and Tan Yuefeng, have recorded varying performance during their tenure, with Zhang achieving a best return of 54.66% and Tan achieving a best return of 65.08% [2]

Group 1 - The core viewpoint of the news is that Changshan Pharmaceutical experienced a stock price increase of 5.22%, reaching 46.80 CNY per share, with a trading volume of 677 million CNY and a turnover rate of 1.62%, resulting in a total market capitalization of 43.012 billion CNY [1] - Changshan Pharmaceutical, established on September 28, 2000, and listed on August 19, 2011, is primarily engaged in the research, production, and sales of heparin series products [1] - The company's main business revenue composition includes 47.47% from water injection preparations, 39.24% from heparin raw materials, and 13.29% from other products [1] Group 2 - From the perspective of fund holdings, one fund under Bosera Fund has a significant position in Changshan Pharmaceutical, with the Bosera National Index 2000 ETF holding 1,400 shares, accounting for 0.55% of the fund's net value, ranking as the fifth-largest holding [2] - The Bosera National Index 2000 ETF, established on November 23, 2023, has a latest scale of 11.7815 million CNY and has achieved a year-to-date return of 38.28%, ranking 1165 out of 4220 in its category [2] - The fund manager, Tang Yibing, has a cumulative tenure of 3 years and 66 days, with the fund's total asset scale at 9.874 billion CNY, achieving the best return of 83.84% and the worst return of -41.93% during his tenure [2]